Learn more about Innovations in Glaucoma Drug Delivery with Dr. Justin Schweitzer

It’s time for Woo’s Wisdom! In our recent webinar titled “Innovations in Glaucoma Drug Delivery: What the Future Holds by Dr. Justin Schweitzer.

Here are some of the key takeaway points

· >90% of patients are non-adherent to topical glaucoma medications

· Topical glaucoma medications can result in ocular side effects, such as neurotoxicity, dryness, redness, and ocular discomfort. The more drops a patient is taking, the more likely they are to be symptomatic.

· The eye has many protective barriers, such as the corneal barrier and the tear film. Only 5% of doses will typically reach the target tissue.

· Innovative glaucoma technology that will be available to us in the future are microdose technology, punctal plug delivery systems, intracanalicular inserts, drug-eluting contact lenses, and so much more.

· The first and only FDA approved dissolvable implant is now available. The implant releases bimatoprost into the eye. It showed great clinical results, reducing IOP by 32-33% and minimal side effects were experienced by subjects.

It is an exciting time to be an eye care practitioner with technology continuing to evolve and changing the way we can continue to take care of patient’s eyes, vision, and quality of life!